Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution
MUMBAI, India, NAPLES, Fla, May 18, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S....
View original →